The International Journal of Biochemistry & Cell Biology
Medicine in focusHIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors
Introduction
For a long time cancer has been considered as a group of diseases driven by genetic modifications including chromosomal translocations, gene amplifications or point mutations in oncogenes or in tumor suppressor genes. However, it is now becoming increasingly clear that epigenetic changes, marked by DNA methylation and histone tail modifications, which convey heritable gene expression patterns, are also central to many human diseases including cancer.
DNA hypermethylation changes at the D17S5 locus in many cancers allowed the positional cloning of HIC1 (Hypermethylated in Cancer 1) as a candidate tumor suppressor located in 17p13.3, a region frequently hypermethylated or deleted in many types of prevalent human tumors (Wales et al., 1995). HIC1 encodes a transcription factor with five Krüppel-like C2H2 zinc finger motifs (Wales et al., 1995, Deltour et al., 1999, Deltour et al., 2002, Pinte et al., 2004b).
In this review, we will first provide an overview of the current understanding of HIC1 function as a sequence-specific transcriptional repressor. We will then describe the studies and animal models which unambiguously defined HIC1 as a tumor suppressor gene epigenetically silenced in many prevalent human cancers.
Section snippets
HIC1: genomic organization
From sequencing analyses of genomic clones and from functional assays, the exon–intron structures of the human and murine HIC1 genes appeared very similar with alternative first exons followed by a unique second exon, containing a coding region and a 3′ untranslated region (Carter et al., 2000, Guerardel et al., 2001). The human HIC1 genomic region contains three promoters that give rise to different alternatively spliced transcripts. Exon 1a is non-coding and associated with the major G–C rich
HIC1: functional aspects
The HIC1 protein is a sequence-specific transcriptional repressor containing three main functional domains (Fig. 2): (i) the N-terminal BTB/POZ (which stands for Broad complex, Tramtrack and Bric à brac/Poxviruses and Zinc finger) domain of about 120 amino-acid is a dimerization domain known to play direct or indirect (through conformational effects) roles in protein–protein interactions. This domain is also an autonomous transcriptional repression domain (Albagli et al., 1995, Stogios et al.,
Inactivation of HIC1 is frequent in cancers
From the beginning, the history of HIC1 has been directly linked to P53. Indeed, loss of heterozygosity (LOH) on the short arm of chromosome 17 (17p) is one of the most common genetic alterations in human cancers and allelic losses most often coincide with mutations in the TP53 gene at 17p13.1 (Ko and Prives, 1996). However, it became rapidly obvious that in breast and ovarian tumors, 17p allelic losses occur at high frequency in regions distal to TP53 and even in the absence of TP53 mutations.
Mouse models of Hic1 and cancer
The epigenetic silencing or deletion of HIC1 in numerous primary tumors and cell lines strongly suggested that it could be a new tumor suppressor gene. Unquestionable clues to the tumor suppressor function of HIC1 have come from the study of Hic1-deficient mice developed in Dr Baylin's laboratory (Chen et al., 2003). Building on this work, two double heterozygote models have shown that Hic1 can cooperate with p53 and Ptch1 in tumorigenesis (Chen et al., 2004, Briggs et al., 2008).
HIC1: a cancer stem cell gene pre-marked for aberrant silencing in ES cells
According to the cancer stem cell hypothesis which is now widely accepted, tumors contain and are driven by a minority cellular population which has retained key stem-cell properties including self-renewal, pluripotency and the ability to reinitiate the tumor mass containing the cellular heterogeneity observed in the original tumor (Jones and Baylin, 2007). Numerous studies have highlighted the key roles of epigenetic signatures in stem-cell identity (reviewed in (Spivakov and Fisher, 2007)).
Conclusions and future directions for research
Thirteen years after its discovery by Dr Baylin's laboratory, HIC1 is now well-recognized as a tumor suppressor gene modulating p53-dependent apoptotic DNA damage responses through direct binding to the SIRT1 promoter; cooperating with Patched, an inhibitor of the Hedgehog pathway to induce medulloblastomas and able to modulate the Wnt pathway.
Despite this significant progress, many basic questions remain unresolved. First, an incomplete picture exists for the mechanisms of transcriptional
Acknowledgements
This review is dedicated to the memory of Christian Lagrou and Jean Coll.
CF and GB were supported by predoctoral fellowships from the Ministère de l’Education Nationale et de la Recherche and from CNRS/Région Nord-Pas de Calais respectively. MT was supported by a post-doctoral fellowship from Association for International Cancer Research (AICR). Our work was supported by funds from CNRS, PASTEUR Institute of Lille, Ligue contre le Cancer (Comité Régional du Septentrion), ARC (Association pour
References (77)
- et al.
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain
Mol Cell
(2003) - et al.
Identification and developmental expression of the zebrafish orthologue of the tumor suppressor gene HIC1
Biochim Biophys Acta
(2004) - et al.
Mechanism of fibroblast growth factor-binding protein 1 repression by TGF-beta
Biochem Biophys Res Commun
(2006) - et al.
Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis
Cancer Cell
(2004) - et al.
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses
Cell
(2005) - et al.
The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved
Biochim Biophys Acta
(1998) - et al.
Characterization of HRG22, a human homologue of the putative tumor suppressor gene HIC1
Biochem Biophys Res Commun
(2001) - et al.
Hedgehog checkpoints in medulloblastoma: the chromosome 17p deletion paradigm
Trends Mol Med
(2005) - et al.
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer
Mol Cell
(2008) - et al.
Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53
J Biol Chem
(2001)
O-GlcNAc glycosylation: a signal for the nuclear transport of cytosolic proteins?
Int J Biochem Cell Biol
SUMO: a history of modification
Mol Cell
The epigenomics of cancer
Cell
DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis
Cancer Lett
POZ for effect—POZ-ZF transcription factors in cancer and development
Trends Cell Biol
Control of developmental regulators by Polycomb in human embryonic stem cells
Cell
Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue
J Urol
The tumor suppressor gene HIC1 (Hypermethylated in Cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties
J Biol Chem
Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers
Gynecol Oncol
Crystal structure of the BTB domain from PLZF
Proc Natl Acad Sci USA
Association between CpG island methylation and microsatellite instability in colorectal cancer
Cancer Res
The BTB/POZ domain: a new protein–protein interaction motif common to DNA- and actin-binding proteins
Cell Growth Differ
Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction?
Nat Rev Cancer
Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma
Genes Dev
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene Hypermethylated in Cancer 1
Oncogene
HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation
Br J Haematol
Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome
Hum Mol Genet
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors
Nat Genet
Transcriptional regulation by C-terminal binding proteins
Int J Biochem Cell Biol
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations
Cancer Res
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B
Proc Natl Acad Sci USA
The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif
Mol Cell Biol
The age of cancer
Nature
REN(KCTD11) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma
Proc Natl Acad Sci USA
Epigenetic patterns in the progression of esophageal adenocarcinoma
Cancer Res
DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history
Cancer Res
Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer
Oncogene
Concepts in sumoylation: a decade on
Nat Rev Mol Cell Biol
Cited by (74)
Epigenome editing in cancer: Advances and challenges for potential therapeutic options
2024, International Review of Cell and Molecular BiologyLoss of Thymine DNA Glycosylase Causes Dysregulation of Bile Acid Homeostasis and Hepatocellular Carcinoma
2020, Cell ReportsCitation Excerpt :However, the biological mechanisms underlying the link between gender, T2D, and HCC are unclear. Aberrant DNA methylation at CpG sites is a common molecular lesion in cancer, often resulting in genomic instability and silencing of specific tumor suppressor genes (Britschgi et al., 2008; Fleuriel et al., 2009; Jones and Baylin, 2002, 2007; Piccolo and Fisher, 2014). Widespread changes in the methylation landscape in cancer cells lead to the aberrant regulation of genes that promote cellular growth and proliferation, culminating in the disruption of cell-cycle control, angiogenesis, and invasion (Hendrich et al., 1999; Jones et al., 1992; Lian et al., 2012).
Reviving the guardian of the genome: Small molecule activators of p53
2017, Pharmacology and TherapeuticsRegulation of Active DNA Demethylation through RAR-Mediated Recruitment of a TET/TDG Complex
2017, Cell ReportsCitation Excerpt :These results strongly suggest that, in the absence of TDG, active demethylation is disrupted, and the Hic1 locus develops a vulnerability to DNA hypermethylation, as has been found in many cancers. The transcriptional repressor Hic1 is located at 17p13.3, a region that is often deleted or hypermethylated (and silenced) in human cancers (Guerardel et al., 2001; Fleuriel et al., 2009). Hypermethylation of the Hic1 locus has been frequently observed in a variety of tumors, including breast, brain, and colon cancers.